Equibles does not estimate personal net worth.
Get an email with a short summary when Replimune Group, Inc. publishes a filing, an earnings call transcript or a press release.
Get REPL alertsEmily Hill is recorded as CFO at Replimune Group, Inc. (REPL). The newest filing on record that lists Emily Hill as CFO at Replimune Group, Inc. (REPL) is dated July 29, 2026. Emily Hill was last confirmed as Board Member at Ptc Therapeutics, Inc. (PTCT) in a filing dated April 27, 2020. Earlier roles on record: CFO at Ptc Therapeutics, Inc. (PTCT) until August 20, 2023. Replimune Group, Inc. reported in an 8-K filed September 19, 2023 that Emily Hill was appointed Chief Financial Officer, effective September 18, 2023. Ptc Therapeutics, Inc. reported in an 8-K filed May 23, 2023 that Emily Hill was terminated as Chief Financial Officer, effective August 20, 2023. The proxy statement of Replimune Group, Inc. reports total compensation of $1,594,953 for Emily Hill in fiscal 2025, including a base salary of $516,500. Disclosed compensation is on record for 3 fiscal years. Emily Hill has spoken on 14 earnings calls across 2 companies, most recently for Replimune Group, Inc. on May 22, 2025. Those appearances were for Ptc Therapeutics, Inc. (PTCT) and Replimune Group, Inc. (REPL). Replimune Group, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Emily Hill spoke on are classified in the Healthcare sector. Other leadership on record at Replimune Group, Inc. includes Dr. Sushil Patel (CEO and Board Member), Sushil Patel (CEO and Board Member), Dieter Weinand (Chairman and Board Member) and 7 others.
“On September 19, 2023, Replimune Group, Inc. ("Replimune") announced the appointment of Emily Hill as its Chief Financial Officer.”
“On May 20, 2023, the Company informed Emily Hill, its Chief Financial Officer, that her employment will be terminated effective as of August 20, 2023, and effective immediately she will cease to serve as the Company's Chief Financial Officer.”
“I'm going to start today with an update on the Investor Relations front. We are excited to be in the process of planning an upcoming Investor Day for June 24.”
“I'll take a few minutes to review our first quarter financial results. Please refer to the earnings press release issued this afternoon for additional details. Beginning with top line results, total revenues for the first quarter were $220 million.”
“I will take a few minutes to review our fourth quarter and full year financial results. Please refer to the earnings press release issued this afternoon for additional detail.”
“Before turning to third quarter financial highlights, I would like to describe the strategic financing of up to $1 billion that we have just closed with Blackstone Life Sciences.”
“In the first half of 2022, we saw continued strong revenue growth and progress in advancing our pipeline across multiple platforms.”
Start not stated–present
Last confirmed July 29, 2026
Start not stated–2020-04-27
Last confirmed by a filing; no departure on record
Start not stated–2023-08-20
Biotechnology · Healthcare
CFO
Biotechnology · Healthcare
Board Member, CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Replimune Group, Inc. (REPL) | Chief Financial Officer | $516,500 | $1,594,953 |
| 2024 | Replimune Group, Inc. (REPL) | Chief Financial Officer | $266,538 | $3,383,157 |
| 2019 | Ptc Therapeutics, Inc. (PTCT) | Chief Financial Officer | $367,530 | $2,336,648 |
